Skip to main content
SpringerLink
Log in

Combined Radiation Therapy and Chemotherapy as an Exclusive Treatment Option in Locally Advanced Inoperable Non-small Cell Lung Cancer

  • Chapter
  • First Online:
Advances in Radiation Oncology in Lung Cancer

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

Abstract

Locally advanced non-small cell lung cancer is one of the major battlegrounds in clinical research in lung cancer. Improved diagnostic and staging opportunities were not followed by increased efforts in a systematic way, e.g., prospective randomized studies which could have helped us optimize our treatment approaches. Although limited prospects for all of the treatment options remain nowadays, the vast minority of patients are treated with surgery in combination with other treatment modalities. The remaining one, and they represent the vast majority of cases treated either alone with radiation therapy or systemic therapy or various combinations in both curative and palliative setting. In curative setting, though, evidence accumulated over the past 3 decades supports superiority of concurrent radiochemotherapy over other existing treatment options. It is expected that with novel radiotherapy technologies and new generations of drugs overall results in this disease are further improved.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Akerley W, Herndon JE Jr, Lyss AP et al (2005) Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study—CALGB 9534. Clin Lung Cancer 7:47–53

    Google Scholar 

  • Albain KS, Crowley JJ, Turrisi AT III et al (2002) Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a southwest oncology group phase II study, SWOG 9019. J Clin Oncol 20:3454–3460

    Google Scholar 

  • Alexander BM, Othus M, Caglar HB, Allen AM (2011) Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 79:1381–1387

    Google Scholar 

  • Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929

    Google Scholar 

  • Antonia SJ, Villegas A, Daniel D et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342–2350

    Google Scholar 

  • Armstrong JG, Burman C, Leibel SA et al (1993) Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 26:685–689

    Google Scholar 

  • Arriagada R, Le Chevalier T, Rekacewicz C et al (1997) Cisplatin-based chemotherapy (CT) in patients with locally advanced non-small cell lung cancer (NSCLC): late analysis of a French randomized trial. Proc Am Soc Clin Oncol 16:16. (abstract)

    Google Scholar 

  • Aupérin A, Le Péchoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:2181–2190

    Google Scholar 

  • Ball D, Bishop J, Smith J et al (1999) A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of a multi-Centre trial. Radiother Oncol 52:129–136

    Google Scholar 

  • Ball D, Mitchell A, Giroux D, Rami-Porta R, The IASLC Staging Committee and Participating Institutions (2013) Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non–small cell lung cancer an analysis of the staging project database of the International Association for the Study of Lung Cancer. J Thorac Oncol 8:315–321

    Google Scholar 

  • Basaki K, Abe Y, Aoki M, Kondo H, Hatayama Y, Nakaji S (2006) Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys 64:449–454

    Google Scholar 

  • Baumann M, Hermann T, Koch R (2005) Continuous hyperfractionated accelerated radiotherapy weekend-less versus conventionalloy fractionated (CF) in non-small cell lung cancer (NSCLC): first results of a phase III randomzied multicentre trial (ARO 97-91). Eur J Cancer 3(Suppl):S323

    Google Scholar 

  • Belani CP, Wang W, Johnson DH (2005a) Phase III study of the eastern cooperative oncology group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23:3760–3767

    Google Scholar 

  • Belani CP, Choy H, Bonomi P et al (2005b) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:5883–5891

    Google Scholar 

  • Belderbos J, Uitterhoeve L, van Zandwijk N, EORTC LCG and RT Group et al (2007) Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 43:114–121

    Google Scholar 

  • Bezjak A, Rumble RB, Rodrigues G et al (2012) Intensity-modulated radiotherapy in the treatment of lung cancer. Clin Oncol (R Coll Radiol) 24:508–520

    Google Scholar 

  • Blanke C, Ansari R, Mantravadi R et al (1995) Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer: a Hoosier oncology group protocol. J Clin Oncol 13:1425–1429

    Google Scholar 

  • Blumenschein GR Jr, Paulus R, Curran WJ et al (2011) Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 29:2312–2318

    Google Scholar 

  • Bonner JA, McGinnis WL, Stella PJ et al (1998) The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced non small cell lung cancer. Results of a north central cancer treatment group phase III study. Cancer 82:1037–1048

    Google Scholar 

  • Bozcuk H, Artac M, Ozdogan M (2010) Correlates of benefit from neoadjuvant chemotherapy before radiotherapy in non-small cell lung cancer: a meta-analytical approach with meta-regression analysis. J BUON 15:43–50

    Google Scholar 

  • Bradley JD, Ieumwananonthachai N, Purdy JA et al (2002) Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 52:49–57

    Google Scholar 

  • Bradley JD, Bae K, Graham MV et al (2010) Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patient with inoperable non-small-cell lung cancer: RTOG 0117. J Clin Oncol 28:2475–2480

    Google Scholar 

  • Bradley JD, Paulus R, Komaki R et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:187–199

    Google Scholar 

  • Bradley JD, Hu C, Komaki R et al (2020) Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol 38:706–t14

    Google Scholar 

  • Brunsvig PF, Kyte JA, Kersten C et al (2011) Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 17:6847–6857

    Google Scholar 

  • Butts C, Socinski MA, Mitchell PL et al (2014) Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage iii nonsmall- cell lung cancer (start): a randomised, double-blind, phase 3 trial. Lancet Oncol 15:59–68

    Google Scholar 

  • Byhardt RW (1999) Toxicities in RTOG combined-modality trials for inoperable non-small-cell lung cancer. Oncology (Huntingt) 13(10 Suppl 5):116–120

    Google Scholar 

  • Byhardt RW, Pajak TF, Emami B, Herskovic A, Doggett RS, Olsen LA (1993) A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of radiation therapy oncology group 84-07. Int J Radiat Oncol Biol Phys 26:459–468

    Google Scholar 

  • Byhardt RW, Scott CB, Ettinger DS et al (1995) Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of radiation therapy oncology group 90-15. Cancer 75:2337–2344

    Google Scholar 

  • Byhardt RW, Scott C, Sause WT et al (1998) Response, toxicity, failure patterns, and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 42:469–478

    Google Scholar 

  • Cakir S, Egehan I (2004) A randomized clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 43:309–316

    Google Scholar 

  • Chen AB, Li L, Cronin A et al (2014) Comparative effectiveness of intensity-modulated versus 3D conformal radiation therapy among medicare patients with stage III lung cancer. J Thorac Oncol 9:1788–1790

    Google Scholar 

  • Choy H, Schwartzberg LS, Dakhil SR et al (2013) Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol 8:1308–1316

    Google Scholar 

  • Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the cancer and leukemia group B and the eastern cooperative oncology group. J Clin Oncol 17:4–11

    Google Scholar 

  • Cox JD, Yesner R, Mietlowski W, Petrovich Z (1979) Influence of cell type on failure pattern after irradiation for locally advanced carcinoma of the lung. Cancer 44:94–98

    Google Scholar 

  • Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF (1990) A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with >69.6 Gy in favorable patients with radiation therapy oncology group stage III non-small cell lung carcinoma: report of radiation therapy oncology group 83-11. J Clin Oncol 8:1543–1555

    Google Scholar 

  • Cox JD, Pajak TF, Asbell S et al (1993) Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 radiation therapy oncology group (RTOG) trials. Int J Radiat Oncol Biol Phys 27:493–498

    Google Scholar 

  • Cullen MH, Billingham LJ, Woodroffe CM et al (1997) Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 1. Results of a randomised trial in patients with localised, inoperable disease. Lung Cancer 18(Suppl 1):5. (abstract 10)

    Google Scholar 

  • Curran WJ Jr, Paulus R, Langer CJ et al (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452–1460

    Google Scholar 

  • Davies AM, Chansky K, Lau DH et al (2006) Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol 24:5242–5246

    Google Scholar 

  • Dehing-Oberije C, De Ruysscher D, van der Weide H et al (2008) Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 70:1039–1044

    Google Scholar 

  • Dieleman EMT, Apollonia LJ, Uitterhoeve ALJ, van Hoek MW et al (2018) Concurrent daily cisplatin and high-dose radiation therapy in patients with stage III non-small cell lung cancer. Int J Radiation Oncol Biol Phys 102:543–551

    Google Scholar 

  • Dillman RO, Seagren SL, Propert KJ et al (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940–945

    Google Scholar 

  • Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR (1996) Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210–1215

    Google Scholar 

  • Durm GA, Jabbour SK, Althouse SK et al (2020) A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN14-179. Cancer 126:4353–4361

    Google Scholar 

  • Eaton BR, Pugh SL, Bradley JD et al (2016) Institutional enrollment and survival among NSCLC patients receiving chemoradiation: NRG oncology radiation therapy oncology group (RTOG) 0617. J Natl Cancer Inst 108:djw034

    Google Scholar 

  • El Sharouni SY, Kal HB, Battermann JJ (2003) Accelerated regrowth of non-small-cell lung tumors after induction chemotherapy. Br J Cancer 89:2184–2189

    Google Scholar 

  • Ezer N, Smith CB, Galsky MD et al (2014) Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer. Radiother Oncol 112:272–278

    Google Scholar 

  • Fournel P, Robinet G, Thomas P, Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie et al (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 study. J Clin Oncol 23:5910–5917

    Google Scholar 

  • Fournel P, Vergnenegre A, Robinet G, GFPC and IFCT Team et al (2016) Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomized phase II trial GFPC—IFCT 02-01. Eur J Cancer 52:181–187

    Google Scholar 

  • Fukuoka M, Niitani H, Suzuki A et al (1992) Phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small cell lung cancer. J Clin Oncol 10:16–20

    Google Scholar 

  • Furuse K, Nishikawa H, Takada Y et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699

    Google Scholar 

  • Furuse K, Hosoe S, Masuda N (2000) Impact of tumor control on survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy (TRT) and chemotherapy (CT). Proc Am Soc Clin Oncol 19(Abstract 1893)

    Google Scholar 

  • Gadgeel SM, Ruckdeschel JC, Patel BB et al (2011) Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. J Thorac Oncol 6:927–933

    Google Scholar 

  • Gandara DR, Chansky K, Albain KS et al (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II southwest oncology group study S9504. J Clin Oncol 21:2004–2010

    Google Scholar 

  • Giraud P, Rosenzweig KE, Yorke E (2001) Radiotherapy for lung cancer: can IMRT decrease the risk of esophagitis? Proc Am Soc Ther Radiol Oncol (ASTRO). San Francisco, Int J Radiat Oncol Biol Phys, pp 355–356 (abstr. #2250)

    Google Scholar 

  • Gkika E, Lenz S, Schimek-Jasch T et al (2020) Efficacy and toxicity of different chemotherapy protocols for concurrent chemoradiation in non-small cell lung cancer—a secondary analysis of the PET plan trial. Cancers 12:3359

    Google Scholar 

  • Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA (2007) The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706–714

    Google Scholar 

  • Goldstraw P, Chansky K, Crowley J et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51

    Google Scholar 

  • Groen HJG, van de Leest AHW, Fokkema E et al (2004) Phase III study of continuous carboplatin over 6 weeks with radiation versus radiation alone in stage III non small cell lung cancer. Ann Oncol 15:427–432

    Google Scholar 

  • Hanna N, Neubauer M, Yiannoutsos C, Hoosier Oncology Group, US Oncology et al (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier oncology group and U.S. oncology. J Clin Oncol 26:5755–5760

    Google Scholar 

  • Harada H, Yamamoto N, Takahashi T et al (2009) Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer. Int J Clin Oncol 14:507–512

    Google Scholar 

  • Harris JP, Murphy JD, Hanlon AL et al (2014) A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 88:872–884

    Google Scholar 

  • Hasegawa T, Futamura Y, Horiba A et al (2016) Phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non–small-cell lung cancer. J Radiat Res 57:50–54

    Google Scholar 

  • Hatton M, Nankivell M, Lyn E et al (2011) Induction chemotherapy and continuous hyperfractionated accelerated radiation therapy (CHART) for patients with lo9cally advanced inoperable non-small-cell lung cancer: the MRC INCH randomized trial. Int J Radiation Oncol Biol Phys 81:712–718

    Google Scholar 

  • Herscher LL, Hahn SM, Kroog G et al (1998) Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J Clin Oncol 16:635–641

    Google Scholar 

  • Holsti LR, Matson K (1980) A randomized study of split-course radiotherapy of lung cancer: long term results. Int J Radiat Oncol Biol Phys 6:977–981

    Google Scholar 

  • Hui R, ÖzgüroÄŸlu M, Villegas A et al (2019) Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol 20:1670–1680

    Google Scholar 

  • Hung M-S, Wu Y-F, Chen Y-C (2019) Efficacy of chemoradiotherapy versus radiation alone in patients with inoperable locally advanced non–small-cell lung cancer. A meta-analysis and systematic review. Medicine 98:27. (e16167)

    Google Scholar 

  • Jain AK, Hughes RS, Sandler AB et al (2009) A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). J Thorac Oncol 4:722–727

    Google Scholar 

  • Jeremic B, Shibamoto Y, Acimovic L, Djuric L (1995) Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452–458

    Google Scholar 

  • Jeremic B, Shibamoto Y, Acimovic LJ, Milisavljevic S (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14:1065–1070

    Google Scholar 

  • Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Milisavljevic S (1998) Concurrent radiochemotherapy for patients with stage III non-small cell lung cancer (NSCLC). Long-term results of a phase II study. Int J Radiat Oncol Biol Phys 42:1091–1096

    Google Scholar 

  • Jeremic B, Shibamoto Y, Acimovic LJ et al (2001) Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without week-end carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 50:19–25

    Google Scholar 

  • Jeremic B, Milicic B, Acimovic L, Milisavljevic S (2005) Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with stage III non-small cell lung cancer (NSCLC). Long-term results of a phase II study. J Clin Oncol 23:1144–1151

    Google Scholar 

  • Johnson DH, Paul DM, Hande KR et al (1996) Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 14:2054–2060

    Google Scholar 

  • Kawano Y, Sasaki T, Yamaguchi H et al (2018) Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non–small cell lung cancer. Lung Cancer 125:136–141

    Google Scholar 

  • Keene KS, Harman EM, Knauf DG, McCarley D, Zlotecki RA (2005) Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer. Am J Clin Oncol 28:217–222

    Google Scholar 

  • Kelly K, Chansky K, Gaspar LE et al (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:2450–2456

    Google Scholar 

  • Komaki R, Scott C, Ettinger D et al (1997) Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: radiation therapy oncology group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 38:149–155

    Google Scholar 

  • Koning CC, Wouterse SJ, Daams JG, Uitterhoeve LL, van den Heuvel MM, Belderbos JS (2013) Toxicity of concurrent radiochemotherapy for locally advanced non–small-cell lung cancer: a systematic review of the literature. Clin Lung Cancer 14:481–487

    Google Scholar 

  • Koshy M, Malik R, Spiotto M, Mahmood U, Rusthovend CG, Sher DJ (2017) Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy. Lung Cancer 108:222–227

    Google Scholar 

  • Le Chevalier T, Arriagada R, Quoix E et al (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417–423

    Google Scholar 

  • Le Chevalier T, Arriagada R, Tarayre M et al (1992) Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma. J Natl Cancer Inst 84:58

    Google Scholar 

  • Le Chevalier T, Brisgand D, Douillard J-Y et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360–367

    Google Scholar 

  • Le Péchoux C, Arriagada R, Le Chevalier T et al (1996) Concurrent cisplatin vindesine and hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 35:519–525

    Google Scholar 

  • Lee C (2006) High-dose 3D chemoradiotherapy in stage III non-small cell lung cancer (NSCLC) at the University of North Carolina: Long-term follow up and late complications. Pro Amer Soc Clin Oncol 24:7145

    Google Scholar 

  • Lee JS, Scott C, Komaki R et al (1996) Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. J Clin Oncol 14:1055–1064

    Google Scholar 

  • Lee P, Bazan JG, Lavori PW et al (2012) Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non–small-cell lung cancer. Clin Lung Cancer 13:52–58

    Google Scholar 

  • Levy A, Bardet E, Lacas B et al (2017) A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. Oncotarget 8:1529–1533

    Google Scholar 

  • Liang HY, Zhou H, Li XL, Yin ZH, Guan P, Zhou BS (2010) Chemo-radiotherapy for advanced non-small cell lung cancer: concurrent or sequential? It’s no longer the question: a systematic review. Int J Cancer 127:718–728

    Google Scholar 

  • Liang J, Bi N, Wu S et al (2017) Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol 28:777–783

    Google Scholar 

  • Lu C, Lee JJ, Komaki R et al (2010) Chemoradiotherapy with or without AE-941 in stage III non–small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst 102:1–7

    Google Scholar 

  • Lynch TJ Jr, Kalish L, Strauss G et al (1994) Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 12:347–352

    Google Scholar 

  • Manegold C, Bergman B, Chemaissani A et al (1997) Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II study in locally-advanced or metastatic non-small cell lung cancer. Ann Oncol 8:525–529

    Google Scholar 

  • Marino P, Preatoni A, Cantoni A (1995) Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 76:593–601

    Google Scholar 

  • Masters GA, Haraf DJ, Hoffman PC et al (1998) Phase I study of vinorelbine, cisplatin and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol 16:2157–2163

    Google Scholar 

  • Mauer AM, Masters GA, Haraf DJ et al (1998) Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16:159–164

    Google Scholar 

  • Mehta MP, Tannehill SP, Adak S et al (1998) Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of eastern cooperative oncology group 4593. J Clin Oncol 16:3518–3523

    Google Scholar 

  • Millward MJ, Zalcberg J, Bishop JF et al (1996) Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 14:750–758

    Google Scholar 

  • Mountain CF (1986) A new international staging system for lung cancer. Chest 89:225S–233S

    Google Scholar 

  • Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717

    Google Scholar 

  • Movsas B, Langer CJ, Ross HJ et al (2010) Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III a/B unresectable non-small cell lung cancer. J Thorac Oncol 5:673–679

    Google Scholar 

  • Nawrocki S, Krzakowski M, Wasilewska-Tesluk E et al (2010) Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study. J Thorac Oncol 5:1255–1262

    Google Scholar 

  • Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Brit Med J 311:899–909

    Google Scholar 

  • Nyman J, Friesland S, Hallqvist A et al (2009) How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish lung cancer study group. Lung Cancer 65:62–67

    Google Scholar 

  • O’Rourke N, Roqué I, Figuls M, Farré Bernadó N, Macbeth F (2010) Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 6:CD002140

    Google Scholar 

  • Oshita F, Noda K, Nishiwaki Y et al (1997) Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol 15:304–309

    Google Scholar 

  • Perez CA, Bauer M, Edelstein S, Gillespie BW, Birch R (1986) Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 12:539–547

    Google Scholar 

  • Perez CA, Pajak TF, Rubin P et al (1987) Long term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the radiation therapy oncology group. Cancer 59:1874–1881

    Google Scholar 

  • Perez-Soler R, Fossella FV, Glisson BS et al (1996) Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14:503–513

    Google Scholar 

  • Petrovich Z, Mietlowski W, Ohanian M, Cox J (1977) Clinical report on the treatment of locally advanced lung cancer. Cancer 40:72–77

    Google Scholar 

  • Petrovich Z, Stanley K, Cox JD, Paig C (1981) Radiotherapy in the management of locally advanced lung cancer of all cell types: final report of randomized trial. Cancer 48:1335–1340

    Google Scholar 

  • Pritchard RS, Anthony SP (1996) Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: a meta-analysis. Ann Intern Med 125:723–729

    Google Scholar 

  • Rami-Porta R, Bolejack V, Giroux DJ, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee et al (2014) Advisory board members and participating institutions. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 9:1618–1624

    Google Scholar 

  • Reynolds RD, O'Dell S (1978) Combination modality therapy in lung cancer: a survival study showing beneficial results of AMCOF (adriamycin, methotrexate, cyclophosphamide, oncovin and 5-fluorouracil). Cancer 42:385–389

    Google Scholar 

  • Robertson JM, Ten Haken RK, Hazuka MB (1997) Dose escalation for non small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 37:1079–1085

    Google Scholar 

  • Rosenman JG, Halle JS, Socinski MA et al (2002) High-dose conformal radiotherapy for treatment of stage IIIA/B non-small cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54:348–356

    Google Scholar 

  • Roswit B, Patno ME, Rapp R et al (1968) The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology 90:688–697

    Google Scholar 

  • Sakai H, Yoneda S, Kobayashi K et al (2004) Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. Lung Cancer 43:195–201

    Google Scholar 

  • Santana-Davila R, Devisetty K, Szabo A et al (2015) Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of veterans health administration data. J Clin Oncol 33:567–574

    Google Scholar 

  • Sasaki T, Seto T, Yamanaka T et al (2018) A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. Br J Cancer 119:675–682

    Google Scholar 

  • Saunders MI, Dische S (1990) Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus. Int J Radiat Oncol Biol Phys 19:1211–1215

    Google Scholar 

  • Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M (1999) Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol 52:137–148

    Google Scholar 

  • Sause WT, Scott C, Taylor S et al (1995) Radiation therapy oncology group 88-08 and eastern cooperative oncology group 4588: preliminary results of a phase III trial in regionally advanced, unresectable nonsmall cell lung cancer. J Natl Cancer Inst 87:198–205

    Google Scholar 

  • Sause W, Kolesar P, Taylor S IV et al (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: radiation therapy oncology group, eastern cooperative oncology group, and southwest oncology group. Chest 117:358–364

    Google Scholar 

  • Schaake-Koning C, van den Bogaert W, Dalesio O et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524–530

    Google Scholar 

  • Schild SE, Fan W, Stinchcombe TE et al (2018) Exploring radiotherapy targeting strategy and dose: a pooled analysis of cooperative group trials of combined modality therapy for stage III non-small cell lung cancer. J Thorac Oncol 13:1171–1182

    Google Scholar 

  • Segawa Y, Kiura K, Takigawa N et al (2010) Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 28:3299–3306

    Google Scholar 

  • Sekine I, Nokihara H, Sumi M et al (2006) Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 1:810–815

    Google Scholar 

  • Shimokawa T, Yamada K, Tanaka H et al (2021) Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer. Cancer Med 10:626–633

    Google Scholar 

  • Socinski MA, Blackstock AW, Bogart JA et al (2008) Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26:2457–2463

    Google Scholar 

  • Soresi E, Borghini U, Zucali R et al (1988) A randomized clinical trial comparing radiation therapy versus radiation therapy plus cis-Dichlorodiamine platinum (II) in the treatment of locally advanced non small cell lung cancer. Semin Oncol 15(Suppl 7):20–25

    Google Scholar 

  • Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy–chemotherapy. Int J Radiat Oncol Biol Phys 5:85–91

    Google Scholar 

  • Steuer CE, Behera M, Ernani V et al (2017) Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non–small-cell lung cancer. A systematic review. JAMA Oncol 3:1120–1129

    Google Scholar 

  • Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo H, Fløtten Ø, Aaseb U (2013) Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian lung cancer study group. Br J Cancer 109:1467–1475

    Google Scholar 

  • Trovo MG, Minatel E, Franchin G et al (1992) Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non small cell lung cancer. Int J Radiat Oncol Biol Phys 24:11–15

    Google Scholar 

  • Ulutin HC, Guden M, Oysul K, Surenkok S, Pak Y (2000) Split-course radiotherapy with or without concurrent or sequential chemotherapy in non-small cell lung cancer. Radiat Med 18:93–96

    Google Scholar 

  • Vokes EE, Gregor A, Turrisi AT (1998) Gemcitabine and radiation therapy for non-small cell lung cancer. Semin Oncol 25(Suppl 4):66–69

    Google Scholar 

  • Vokes EE, Herndon JE II, Crawford J et al (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20:4191–4198

    Google Scholar 

  • Wang L, Wu S, Ou G et al (2012) Randomized phase II study of concurrent cisplatin/ etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 77:89–96

    Google Scholar 

  • Werner-Wasik M, Swann RS, Bradley J et al (2008) Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the radiation therapy oncology group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70:385–390

    Google Scholar 

  • White JE, Chen T, Reed R et al (1982) Limited squamous cell carcinoma of the lung: a southwest oncology group randomised study of radiation with or without doxorubicin chemotherapy and with or without levamisole immunotherapy. Cancer Treat Rep 66:1113–1120

    Google Scholar 

  • Wozniak AJ, Moon J, Thomas CR Jr et al (2015) A Pilot trial of cisplatin/etoposide/radiotherapy followed by consolidation docetaxel and the combination of bevacizumab (NSC-704865) in patients with inoperable locally advanced stage III non-small-cell lung cancer: SWOG S0533. Clin Lung Cancer 16:340–347

    Google Scholar 

  • Yamamoto N, Nakagawa K, Nishimura Y et al (2010) Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan thoracic oncology group WJTOG0105. J Clin Oncol 28:3739–3745

    Google Scholar 

  • Ying M, Liu J, Zhou W, Weng K, Long B, Wang Y (2019) The role of additional chemotherapy in combination with concurrent chemoradiotherapy for locally advanced inoperable non-small cell lung cancer, a systematic review and meta-analysis of 12 randomized trials. Cancer Investig 37:376–386

    Google Scholar 

  • Yorke E (2001) Advantages of IMRT for dose escalation in radiation therapy for lung cancer. Med Phys 28:1291–1294

    Google Scholar 

  • Zhang Q-N, Wang D-L, Wang X-H et al (2012) Non-conventional radiotherapy versus conventional radiotherapy for inoperable non-small-cell lung cancer: a meta-analysis of randomized clinical trials. Thorac Cancer 3:269–279

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, University of Kragujevac, Kragujevac, Serbia

    Branislav Jeremić

  2. University Hospital to East Slovakia Institute of Oncology, Kosice, Slovakia

    Pavol Dubinsky

  3. Department of Thoracic Surgery, University Clinical Center, Kragujevac, Serbia

    Slobodan Milisavljević

  4. Department of Clinical Oncology, Caucasus Medical Center, Tbilisi, Georgia

    Ivane Kiladze

Authors
  1. Branislav Jeremić
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pavol Dubinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Slobodan Milisavljević
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ivane Kiladze
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Branislav Jeremić .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Kragujevac, Kragujevac, Serbia

    Branislav Jeremić

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jeremić, B., Dubinsky, P., Milisavljević, S., Kiladze, I. (2021). Combined Radiation Therapy and Chemotherapy as an Exclusive Treatment Option in Locally Advanced Inoperable Non-small Cell Lung Cancer. In: Jeremić, B. (eds) Advances in Radiation Oncology in Lung Cancer. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/174_2021_277

Download citation

  • DOI: https://doi.org/10.1007/174_2021_277

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-34846-4

  • Online ISBN: 978-3-031-34847-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation